315 related articles for article (PubMed ID: 37016029)
1. Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for Translational Research.
Chan HW; Chow S; Zhang X; Zhao Y; Tong HHY; Chow SF
AAPS PharmSciTech; 2023 Apr; 24(4):98. PubMed ID: 37016029
[TBL] [Abstract][Full Text] [Related]
2. Integrated continuous manufacturing of inhalable remdesivir nanoagglomerate dry powders: Design, optimization and therapeutic potential for respiratory viral infections.
Chan HW; Lee HW; Chow S; Lam DCL; Chow SF
Int J Pharm; 2023 Sep; 644():123303. PubMed ID: 37579825
[TBL] [Abstract][Full Text] [Related]
3. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
[TBL] [Abstract][Full Text] [Related]
4. Inhalable nanoparticulate powders for respiratory delivery.
Muralidharan P; Malapit M; Mallory E; Hayes D; Mansour HM
Nanomedicine; 2015 Jul; 11(5):1189-99. PubMed ID: 25659645
[TBL] [Abstract][Full Text] [Related]
5. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization,
Acosta MF; Muralidharan P; Grijalva CL; Abrahamson MD; Hayes D; Fineman JR; Black SM; Mansour HM
Ther Adv Respir Dis; 2021; 15():1753466621998245. PubMed ID: 33719747
[TBL] [Abstract][Full Text] [Related]
6. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
Lin YW; Wong J; Qu L; Chan HK; Zhou QT
Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
[TBL] [Abstract][Full Text] [Related]
7. Particle engineering in dry powders for inhalation.
Scherließ R; Bock S; Bungert N; Neustock A; Valentin L
Eur J Pharm Sci; 2022 May; 172():106158. PubMed ID: 35248734
[TBL] [Abstract][Full Text] [Related]
8. Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.
Chang RYK; Chan HK
Pharm Res; 2022 Dec; 39(12):3047-3061. PubMed ID: 36071354
[TBL] [Abstract][Full Text] [Related]
9. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
Okuda T
Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
[TBL] [Abstract][Full Text] [Related]
10. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
12. Physical stability of dry powder inhaler formulations.
Shetty N; Cipolla D; Park H; Zhou QT
Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
[No Abstract] [Full Text] [Related]
13. A Review on Micro and Nanoengineering in Powder-Based Pulmonary Drug Delivery.
Pasero L; Susa F; Limongi T; Pisano R
Int J Pharm; 2024 Jun; 659():124248. PubMed ID: 38782150
[TBL] [Abstract][Full Text] [Related]
14. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
15. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
16. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
Stegemann S; Faulhammer E; Pinto JT; Paudel A
Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
[TBL] [Abstract][Full Text] [Related]
17. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
18. Dry powder formulation of azithromycin for COVID-19 therapeutics.
Chan SHY; Sheikh K; Zariwala MG; Somavarapu S
J Microencapsul; 2023 Jun; 40(4):217-232. PubMed ID: 36752024
[TBL] [Abstract][Full Text] [Related]
19. Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.
Gomez AI; Acosta MF; Muralidharan P; Yuan JX; Black SM; Hayes D; Mansour HM
Pulm Pharmacol Ther; 2020 Oct; 64():101975. PubMed ID: 33137515
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
Albariqi AH; Ke WR; Khanal D; Kalfas S; Tang P; Britton WJ; Drago J; Chan HK
J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):239-251. PubMed ID: 35275749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
